Istesso Limited (“Istesso’’) today announces that it has completed a second close of its recently reported financing, adding a further £4 million to the £6 million raised in December and bringing the total amount to £10 million.
For further information, please contact:
Dr Sam Williams, Executive Chairman +44 207 444 0066
Notes to Editors
Istesso is a drug discovery and development company working in the field of immunometabolism. Istesso’s products work by reprogramming cellular metabolism and have applications in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis, as well as cancer. For more information please visit www.istesso.co.uk.